370,000 Shares in Alphatec Holdings, Inc. (NASDAQ:ATEC) Bought by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC acquired a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 370,000 shares of the medical technology company's stock, valued at approximately $2,057,000. Alphatec accounts for approximately 1.5% of AlphaCentric Advisors LLC's portfolio, making the stock its 18th biggest holding. AlphaCentric Advisors LLC owned 0.26% of Alphatec at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ATEC. Van ECK Associates Corp lifted its holdings in shares of Alphatec by 11.8% during the 2nd quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company's stock valued at $128,000 after buying an additional 1,300 shares during the last quarter. ProShare Advisors LLC grew its holdings in Alphatec by 8.5% during the first quarter. ProShare Advisors LLC now owns 16,572 shares of the medical technology company's stock valued at $229,000 after purchasing an additional 1,304 shares during the last quarter. Bayesian Capital Management LP lifted its stake in shares of Alphatec by 5.6% in the first quarter. Bayesian Capital Management LP now owns 27,000 shares of the medical technology company's stock worth $372,000 after buying an additional 1,442 shares during the last quarter. Cetera Advisors LLC boosted its holdings in shares of Alphatec by 15.6% during the 1st quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company's stock worth $175,000 after buying an additional 1,720 shares during the period. Finally, Comerica Bank grew its stake in Alphatec by 64.8% in the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company's stock valued at $89,000 after buying an additional 2,534 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company's stock.

Alphatec Price Performance

Shares of NASDAQ ATEC traded up $0.21 during mid-day trading on Tuesday, hitting $8.57. 1,984,860 shares of the stock were exchanged, compared to its average volume of 1,955,611. The stock's fifty day simple moving average is $5.87 and its two-hundred day simple moving average is $8.56. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $17.34. The company has a market cap of $1.21 billion, a P/E ratio of -6.53 and a beta of 1.31.

Insider Activity

In related news, Director David M. Demski acquired 50,000 shares of the firm's stock in a transaction on Wednesday, August 21st. The shares were purchased at an average price of $5.67 per share, with a total value of $283,500.00. Following the acquisition, the director now directly owns 288,441 shares in the company, valued at $1,635,460.47. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 22.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ATEC has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Thursday, October 31st. Barclays assumed coverage on Alphatec in a research report on Monday, July 8th. They issued an "overweight" rating and a $19.00 price objective for the company. Stifel Nicolaus dropped their target price on shares of Alphatec from $19.00 to $16.00 and set a "buy" rating on the stock in a research report on Thursday, August 1st. Canaccord Genuity Group restated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Friday, August 30th. Finally, Morgan Stanley lowered shares of Alphatec from an "overweight" rating to an "equal weight" rating in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.